one more bad quarter…sales and margin degrowth… no commetary from management…
Posts in category Value Pickr
Great articles to read on the web (27-07-2022)
Insights on second-level thinking and contrarian investment for superior returns. An article by Howard Marks of Oaktree Capital Management.
https://www.oaktreecapital.com/insights/memo/i-beg-to-differ
Great articles to read on the web (27-07-2022)
Excellent article by Anand Sridharan of Nalanda Capital
NGL Fine-Chem (Animal Health + Human Health + Vet Formulations) (27-07-2022)
Notes from AR iro NGL Finechem for FY 21-22 -
- A prominent animal healthcare company in India with a global footprint. A leading manufacturer of animal APIs, advanced intermediates and finished dosage forms. Has 3 state of the art manufacturing facilities in Maharashtra - two at Tarapur and one at Navi Mumbai.
- Current product portfolio of 21 animal APIs, 02 human APIs, 04 intermediates and 10 formulations. Revenue breakdown -
Veterinary APIs - 82 pc
Human APIs - 7 pc
Intermediates - 9 pc
Formulations - 3 pc
Geography wise revenue breakdown -
India - 24 pc
Europe - 28 pc
US - 3 pc
Asia Pacific - 30 pc
RoW - 15 pc
Company has 50 pc plus mkt share in top 3 of its products.
- Key performance highlights -
Veterinary APIs grew 26 YoY in FY 21-22
Revenues increased to 318 cr from 258 cr
EBITDA at 69 cr vs 77 cr
PAT at 53 cr vs 55 cr
EBITDA margins at 21 pc vs 30 pc
Aim to launch 3-4 products per year. Currently have 5 molecules in pipeline, each with multi step synthesis. These products are likely to be margin accretive. Their newly launched poultry molecule has shown wide acceptance and is clocking in good sales. Company completed expansion at Macrotech’s plant ( subsidiary ) in the FY 21-22. Also added capacities with brown filed expansion at Tarapur.
- Animal healthcare mkt likely to grow at 5pc CAGR upto 2027. Bulk of company’s products cater to the cattle market and the company expects the trend to continue in future as well. Company’s 4 yr CAGR for revenue, EBITDA and PAT stands at 27 pc, 34 pc and 41 pc !!! Company is likely to out source 15 pc of its manufacturing to cater to increasing demand. Also, 50 pc capacity expansion ( Greenfield ) at Tarapur is lined up. Total outlay for this capex is 140 cr. Likely to be completed by next FY.
Disc : invested, biased.
Ranvir’s Portfolio (27-07-2022)
Notes from AR iro NGL Finechem for FY 21-22 -
-
A prominent animal healthcare company in India with a global footprint. A leading manufacturer of animal APIs, advanced intermediates and finished dosage forms. Has 3 state of the art manufacturing facilities in Maharashtra - two at Tarapur and one at Navi Mumbai.
-
Current product portfolio of 21 animal APIs, 02 human APIs, 04 intermediates and 10 formulations. Revenue breakdown -
Veterinary APIs - 82 pc
Human APIs - 7 pc
Intermediates - 9 pc
Formulations - 3 pc
Geography wise revenue breakdown -
India - 24 pc
Europe - 28 pc
US - 3 pc
Asia Pacific - 30 pc
RoW - 15 pc
Company has 50 pc plus mkt share in top 3 of its products.
- Key performance highlights -
Veterinary APIs grew 26 YoY in FY 21-22
Revenues increased to 318 cr from 258 cr
EBITDA at 69 cr vs 77 cr
PAT at 53 cr vs 55 cr
EBITDA margins at 21 pc vs 30 pc
Aim to launch 3-4 products per year. Currently have 5 molecules in pipeline, each with multi step synthesis. These products are likely to be margin accretive. Their newly launched poultry molecule has shown wide acceptance and is clocking in good sales. Company completed expansion at Macrotech’s plant ( subsidiary ) in the FY 21-22. Also added capacities with brown filed expansion at Tarapur.
- Animal healthcare mkt likely to grow at 5pc CAGR upto 2027. Bulk of company’s products cater to the cattle market and the company expects the trend to continue in future as well. Company’s 4 yr CAGR for revenue, EBITDA and PAT stands at 27 pc, 34 pc and 41 pc !!! Company is likely to out source 15 pc of its manufacturing to cater to increasing demand. Also, 50 pc capacity expansion ( Greenfield ) at Tarapur is lined up. Total outlay for this capex is 140 cr. Likely to be completed by next FY.
Disc : invested, biased.
Techno electric engg ltd (27-07-2022)
I saw some post on twitter that data center work is on
Company started buying shares yesterday as per open market buyback, let us hope it gives a floor and results provide tailwind for stock to go up…
Shalby Hospitals (27-07-2022)
detailed investor presentation
Tejas Networks – Product based IT business in a favored sector? (27-07-2022)
Something on similar lines from South Korea
Axtel Industries Limited: A proxy to packaged food industry (27-07-2022)
Any idea why receivable days has jumped in FY22 vs previous years?
Tatva Chintan – A catalyst for growth (27-07-2022)
In Automobiles SDA usage is in Catalytic Converters .
SDAs are the key building blocks for manufacturing high-precision zeolite which is used in automotive emission control, petrochemicals, continuous flow chemistry,
Dont think its used in gasoline .